New Biweekly GLP-1 Shot Lowers Blood Sugar, Supports Weight Loss

• A brand new GLP-1 remedy demonstrated efficacy in lowering blood sugar in individuals with sort 2 diabetes in a part 2b medical trial.
• Bofanglutide is a biweekly (as soon as each 2 weeks) injection in comparison with once-weekly pictures like Ozempic and Wegovy.
• The brand new biweekly GLP-1 additionally led to weight reduction and enchancment in cardiometabolic threat components.

GLP-1 medicine like Ozempic and Wegovy are groundbreaking therapies for sort 2 diabetes and weight problems.

As different drug producers be a part of the GLP-1 race, Gan & Lee Prescribed drugs in Beijing, China, is growing a novel biweekly GLP-1 for weight reduction.

In a part 2b randomized medical trial, bofanglutide demonstrated a robust efficacy in lowering blood sugar in individuals with sort 2 diabetes.

If accepted, a biweekly shot may supply an alternative choice to once-weekly GLP-1 injections for the needle-averse.

The part 2b medical trial of bofanglutide included 272 adults with sort 2 diabetes, with a median age of fifty.8, from 37 websites throughout China. The individuals had been divided into 5 therapy teams:

• bofanglutide 12 mg (biweekly)
• bofanglutide 18 mg (biweekly)
• bofanglutide 24mg (biweekly)
• bofanglutide 24mg (as soon as weekly)
• semaglutide 1mg (as soon as weekly)

The first measurement the researchers centered on was HbA1c levels from the baseline to the 24-week follow-up.

On the finish of 24 weeks, all bofanglutide teams confirmed vital reductions in blood sugar ranges.

Individuals taking bofanglutide skilled weight reduction and enhancements in varied cardiometabolic threat components.

In some circumstances, blood sugar reductions amongst these taking bofanglutide had been barely better than these taking semaglutide.

Nevertheless, the semaglutide group obtained a comparatively low dose, highlighting the necessity for additional examine.

“Extra real-world comparisons are wanted to find out whether or not this might be more practical than semaglutide,” mentioned Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Heart at Orange Coast Medical Heart in Fountain Valley, CA. Ali wasn’t concerned within the examine.

The trial’s findings additionally recommend that bofanglutide may assist handle diabetes and weight problems.

Nevertheless, Clare Thompson, a normal practitioner and lead of the burden administration service at Cadogan Clinic in the UK, additional famous the examine’s limitations. Thompson wasn’t concerned within the examine.

“The examine is restricted by its comparatively small dimension and by inhabitants information from a Chinese language cohort, the place the beginning BMI could also be a lot decrease than in Western populations,” she instructed Healthline.

“[It] doesn’t present what occurs to sufferers after stopping these medicines or titrating right down to a upkeep dose. Twenty-four weeks is sort of a brief commentary interval for drawing full and significant conclusions,” she mentioned.

All GLP-1 medicine — semaglutide, bofanglutide, or tirzepatide — might trigger side effects.

Round 40% of people utilizing a GLP-1 remedy expertise nausea, vomiting, diarrhea, or constipation.

Gastrointestinal signs, akin to nausea, are among the many most common.

The researchers who carried out the trial discovered that whereas these unwanted side effects could also be extra frequent with bofanglutide, they had been typically delicate.

Different unwanted side effects might embody a response on the injection website. This will embody swelling, ache or discomfort, discoloration, or a rash.

In the event you take a GLP-1 and expertise unwanted side effects that concern you, communicate along with your healthcare skilled.